Literature DB >> 16905642

Serum cholesterol levels and the risk of Parkinson's disease.

Lonneke M L de Lau1, Peter J Koudstaal, Albert Hofman, Monique M B Breteler.   

Abstract

Several recent findings suggest a role of lipid and cholesterol metabolism in the pathogenesis of Parkinson's disease. Therefore, the authors examined the association between serum levels of cholesterol and the risk of Parkinson's disease in the prospective, population-based Rotterdam Study among 6,465 subjects aged 55 or more years with repeated in-person examination and on average 9.4 years of follow-up (1990-2004). Higher serum levels of total cholesterol were associated with a significantly decreased risk of Parkinson's disease (age- and sex-adjusted hazard ratio per mmol/liter increase in cholesterol = 0.77, 95% confidence interval: 0.64, 0.94), with evidence for a dose-effect relation. The association was restricted to women and remained unchanged after adjustment for multiple potential confounders. These findings may indicate a role of lipids in the pathogenesis of Parkinson's disease. Alternatively, they could reflect the strong correlation-especially in women-between levels of serum cholesterol and the antioxidant coenzyme Q10. If confirmed, this would provide further support for an important role of oxidative stress in the pathogenesis of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16905642     DOI: 10.1093/aje/kwj283

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  62 in total

1.  The oxysterol 27-hydroxycholesterol regulates α-synuclein and tyrosine hydroxylase expression levels in human neuroblastoma cells through modulation of liver X receptors and estrogen receptors--relevance to Parkinson's disease.

Authors:  Gurdeep Marwarha; Turk Rhen; Trevor Schommer; Othman Ghribi
Journal:  J Neurochem       Date:  2011-10-24       Impact factor: 5.372

Review 2.  Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.

Authors:  Amaal AlDakheel; Lorraine V Kalia; Anthony E Lang
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

3.  Dietary fats, cholesterol and iron as risk factors for Parkinson's disease.

Authors:  Karen M Powers; Terri Smith-Weller; Gary M Franklin; W T Longstreth; Phillip D Swanson; Harvey Checkoway
Journal:  Parkinsonism Relat Disord       Date:  2008-04-18       Impact factor: 4.891

4.  Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK.

Authors:  Claudia Becker; Susan S Jick; Christoph R Meier
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

5.  Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study.

Authors:  Xuemei Huang; Alvaro Alonso; Xuguang Guo; David M Umbach; Maya L Lichtenstein; Christie M Ballantyne; Richard B Mailman; Thomas H Mosley; Honglei Chen
Journal:  Mov Disord       Date:  2015-01-14       Impact factor: 10.338

Review 6.  Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis.

Authors:  W Gibson Wood; Ling Li; Walter E Müller; Gunter P Eckert
Journal:  J Neurochem       Date:  2014-01-02       Impact factor: 5.372

7.  Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease.

Authors:  Kelly Claire Simon; Honglei Chen; Michael Schwarzschild; Alberto Ascherio
Journal:  Neurology       Date:  2007-08-29       Impact factor: 9.910

8.  Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Honglei Chen; Thomas H Mosley; Alvaro Alonso; Xuemei Huang
Journal:  Am J Epidemiol       Date:  2009-03-18       Impact factor: 4.897

9.  Diet and age interactions with regards to cholesterol regulation and brain pathogenesis.

Authors:  Romina M Uranga; Jeffrey N Keller
Journal:  Curr Gerontol Geriatr Res       Date:  2010-04-11

10.  Reply: Plasma cholesterol and Parkinson's disease: Is the puzzle only apparent?

Authors:  Xuemei Huang; Honglei Chen; Helen Petrovitch; Richard Mailman; Webster Ross
Journal:  Mov Disord       Date:  2010-01-15       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.